Retatrutide: Ozempic 2.0?

Hong Kong Yanpep International
The step-up pattern is real - tirzepatide and retatrutide hitting harder for ozempic non-responders tracks with the mechanism difference. Dual and triple agonism recruits more pathways than sema alone.
 
the Napster-to-streaming arc is the right historical parallel for where GLP-1 access is probably heading - the current gray zone access pattern tends to be a transitional stage that compresses as cost drops and legitimate access expands. what looks like a permanent enforcement problem usually resolves when the product becomes cheap enough that the alternative stops making sense economically for most people
 
Back
Top